Thermo Fisher Wins Three R&D 100 Awards for Breakthroughs In Precision Medicine and Cell Therapy Research

Thermo Fisher Scientific Inc., the world leader in serving science, has earned three R&D 100 Awards in the Analytical/Test category, honoring its commitment to innovation in areas such as precision medicine and cell and gene therapy research. These awards celebrate the company’s role in advancing breakthroughs in instrumentation, testing systems, laboratory equipment, and life sciences technologies.

“Our Mission drives our innovation, ensuring we’re delivering solutions that help push our customers’ discovery forward and expand the boundaries of science. We are honored to be recognized for our commitment to helping drive scientific progress through advanced technology. From realizing the potential of precision medicine to automating time-consuming workflows and ensuring the safety of treatments, we’re proud to help scientists achieve deeper insights, faster timelines and safer products as we work together to bring life-changing therapies to patients,” said Karen Nelson, chief scientific officer, Thermo Fisher Scientific. 

The awarded products include the Thermo Scientific™ Stellar™ Mass Spectrometer, which offers tenfold higher sensitivity and can analyze five times more compounds than traditional systems, accelerating biomarker discovery and drug development. The Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor introduces the first fully automated maxi-scale plasmid DNA purification system, cutting processing time in half and minimizing contamination risks. Meanwhile, the SteriSEQ™ Rapid Sterility Testing Kit leverages qPCR to deliver reliable sterility results in less than a day, enabling safer and faster delivery of cell therapies.

Now in its 63rd year, the R&D 100 Awards, sponsored by R&D World Magazine, recognize the 100 most innovative technologies worldwide. Thermo Fisher’s recognition reinforces its leadership in developing next-generation scientific tools that not only streamline workflows but also support the creation of advanced therapies for complex diseases, strengthening progress in translational research and biopharmaceutical innovation.